[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Another explanation for the $LLY $NKTR pretrial delay return to rezpeg collaboration settlement good reason for the trial delay without any explanation and likely re-rate NKTRs valuation upward several-fold over @seedy19tron litigation model Thoughts X. From conflict to collaboration $LLY and $NKTR already built rezpeg together it was a Lilly-led program from their 2017 partnership. The fallout was about how Lilly ran the trials and Nektars claim that Lillys study design and communication effectively undermined the drugs perceived value. Now with Nektars independent Phase 2b"
X Link @JD4for4 2025-10-16T12:28Z 8291 followers, 7279 engagements
"$NKTR For those talking about another offering on top of Julys miniscule $115m heres a quote from the CEO (Aug 7) about financing future activities. We don't have any plans for additional financing at this point. We have a number of important data catalysts ahead of us. And we're actively talking to partners about the potential to collaborate on REZPEG. And thats including strategics as well as financing partners. There's ways to do this that are a collaboration with another company. There's also ways to do this with nondilutive financial methods. So we also have some -- we also have other"
X Link @FeldtInvesting 2025-10-16T09:02Z XXX followers, 2150 engagements
"pretty sus for the court to vacate the $NKTR v $LLY case when there are tons of trivial cases on the books"
X Link @basadomente 2025-10-16T06:14Z XXX followers, XXX engagements
"My EOY predictions; $NKTR acquired by $LLY by November 23rd $ABVX breaks $XXX within X mos acquired post-JPM by $JNJ for $XXX $CRVS next long through 2026"
X Link @lifesci31 2025-10-16T01:31Z X followers, XXX engagements